Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Breast Cancer Research and Treatment
|
January 1, 1994
Arimidex: a potent and selective fourth-generation aromatase inhibitor
P V Plourde, M Dyroff, M Dukes
American Journal of Diseases of Children (1960)
|
November 1, 1983
Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies
P V Plourde, H E Kulin, S J Santner
Journal of the American Academy of Dermatology
|
May 1, 1984
Acanthosis nigricans and insulin resistance
P V Plourde, J G Marks, J M Hammond
Seminars in Oncology
|
August 1, 1996
Aromatase inhibitors in metastatic breast cancer
A U Buzdar, P V Plourde, G N Hortobagyi
The Journal of Clinical Endocrinology and Metabolism
|
April 1, 1985
Impotence associated with low biological to immunological ratio of luteinizing hormone in a man with a pituitary stone
P V Plourde, M Dufau, N Plourde, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
April 1, 1997
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer
A U Buzdar, W Jonat, A Howell, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
June 1, 1995
ARIMIDEX: a new oral, once-a-day aromatase inhibitor
P V Plourde, M Dyroff, M Dowsett, et al.
Archives of Internal Medicine
|
June 1, 1986
Thallium-technetium parathyroid scan. A useful noninvasive technique for localization of abnormal parathyroid tissue
A Manni, R M Basarab, P V Plourde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group
A Buzdar, W Jonat, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
S Damodaran, C C O'Sullivan, A Elkhanany, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Breast Cancer Research and Treatment
|
January 1, 1994
Arimidex: a potent and selective fourth-generation aromatase inhibitor
P V Plourde, M Dyroff, M Dukes
American Journal of Diseases of Children (1960)
|
November 1, 1983
Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies
P V Plourde, H E Kulin, S J Santner
Journal of the American Academy of Dermatology
|
May 1, 1984
Acanthosis nigricans and insulin resistance
P V Plourde, J G Marks, J M Hammond
Seminars in Oncology
|
August 1, 1996
Aromatase inhibitors in metastatic breast cancer
A U Buzdar, P V Plourde, G N Hortobagyi
The Journal of Clinical Endocrinology and Metabolism
|
April 1, 1985
Impotence associated with low biological to immunological ratio of luteinizing hormone in a man with a pituitary stone
P V Plourde, M Dufau, N Plourde, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
April 1, 1997
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer
A U Buzdar, W Jonat, A Howell, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
June 1, 1995
ARIMIDEX: a new oral, once-a-day aromatase inhibitor
P V Plourde, M Dyroff, M Dowsett, et al.
Archives of Internal Medicine
|
June 1, 1986
Thallium-technetium parathyroid scan. A useful noninvasive technique for localization of abnormal parathyroid tissue
A Manni, R M Basarab, P V Plourde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group
A Buzdar, W Jonat, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
S Damodaran, C C O'Sullivan, A Elkhanany, et al.
Page
of 2